Loading...
Loading...
Dataset URI:
10.6084/m9.figshare.34841496.v1Oral supplements are widely used for dry eye disease (DED), but their effects and relative merits are uncertain. Five databases (to 18 June 2026) and two trial registers were searched for randomized trials of oral supplements against placebo or no supplement. Classes were pooled against control in sign-confirmed DED with random-effects models and Hartung-Knapp intervals. A network model was exploratory. Certainty was rated with GRADE. We included 57 trials (6,615 participants), 29 (2,272 participants) in the primary analyses. The Ocular Surface Disease Index differed by −4.4 points (95% CI −9.0 to 0.2) with marine omega-3 (6 trials) and by −5.2 points (−8.8 to −1.7) with omega-3 combinations (4 trials), both below the 7-point threshold for an important difference. Marine omega-3 increased tear break-up time by 1.32 seconds (0.05 to 2.60, prediction interval −1.3 to 4.0). Certainty was very low for 40 of 48 comparisons and low for 8. All comparisons between classes were indirect, across dissimilar trials and controls, with very low certainty. Twenty trials reported no safety data. Some classes had favorable average estimates against control, but effects were small, imprecise or inconsistent, and classes cannot be ranked. Current evidence does not support routine use. CRD420261432518, https://www.crd.york.ac.uk/PROSPERO/view/CRD420261432518.
Keyword(s):
Biological Sciences not elsewhere classified; Biotechnology; Dietary supplements; dry eye disease; GRADE.
MeSH Term(s):
Grants and Funding:
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)